Join the future of rUTI mitigation by pre-registering for our ImmunoRing clinical study in the Dutch Brainport Region. Be one of the first to experience ImmunoRing and help many patients by supporting this groundbreaking research. The clinical study will be held after METC approval. It will be organized together with Wageningen University and Bernhoven hospital in Uden.

Selected participants will be invited to experience the latest ImmunoRing technology, prescribed by a registered general practicioner or specialist. This pilot is designed for women who suffer from frequent urinary tract infections ( > 4 times per year) that are typically treated with antibiotics.  

How the study looks like?

As part of the study, we will collect urine samples from you over 5 days during ImmunoRing treatment to assess its effectiveness. Be among the first to explore this innovative approach to managing recurrent UTIs—pre-register now.  

In the studies we wish to invite patients that suffer from 3 or more episodes of rUTI per year, and that can recognize the start of an episode early. Also in normal care (which will continue unchanged) these patients should normally only take antibiotics when needed, and normally a few days later than when they recognize the start of an episode. 

To measure the bacterial growth, the immune response, and infection resolution we ask to collect morning urine samples during 2 weeks, that we will collect at the patient’s door and analyse in a certified medical laboratory. 

In a pre-study that we’re planning on starting August 2026, no treatment is yet offered, but urine analysis is done to be able to determine how many samples will be needed in the full study. 

The full study will start after METC approval. During that study, patients will get an ImmunoRing delivered at home and use it three times spread over the first days of an episode. The study will be randomized and double blind which means that for each two episodes one time the device will be active and the other time placebo. Patients and investigators will not have information what is active and what is placebo. 

It is important that normal care for the episodes continues unchanged, including how it is decided to use antibiotics and when. In that way true and objective evidence can be gathered on whether and how ImmunoRing reduces pain, helps resolve the infection quickly, and reduce how often antibiotics are needed.